Weight Loss, Obesity Medication, and Risk of Obesity-Associated Cancer: A Meta-Analysis of Randomized Controlled Trials.
Coagonists, including cagrilintide, may reduce obesity-associated cancer risk, but further research is needed to confirm these findings.
Where it sits
this study against the rest of the cagrilintide (am833) corpusSummary and findings
This meta-analysis evaluated the impact of antiobesity medications (AOMs) on obesity-associated cancer risk across 25 randomized controlled trials with 40,731 participants. Overall, AOMs did not significantly alter cancer risk, but coagonists like cagrilintide showed a reduced risk. The relative risk for coagonists was 0.43, suggesting a potential benefit in this subgroup.
Abstract
<h4>Objective</h4>This study aimed to determine whether weight reduction mediated by antiobesity medications (AOMs) contributes to the risk reduction in obesity-associated cancer.<h4>Methods</h4>PubMed, Embase, the Cochrane Central Register of Controlled Trials, Web of Science, and the ClinicalTrials.gov website were systematically searched for randomized controlled trials of AOMs from inception to December 2024. Relative risks were calculated using a random-effects model.<h4>Results</h4>The analysis included 25 randomized controlled trials with 40,731 participants. Compared with placebo, AOMs showed no association with the risk of overall obesity-related cancer (RR = 1.03, 95% CI: 0.78 to 1.37) or site-specific cancer. Consistently, every 5 kg weight reduction mediated by AOMs was not associated with the risk of overall obesity-related cancer (RR = 0.97, 95% CI: 0.84 to 1.12) or site-specific cancer. However, subgroup analysis revealed that coagonists (tirzepatide, cotadutide, and cagrilintide) significantly reduced overall obesity-associated cancer risk (RR = 0.43, 95% CI: 0.19 to 0.97), and every 5 kg weight reduction mediated by coagonists was marginally associated with a reduced overall obesity-associated cancer risk (RR = 0.79, 95% CI: 0.62 to 1.00).<h4>Conclusions</h4>Weight reduction mediated by current AOMs was not associated with a reduced risk of overall or site-specific obesity-associated cancer in patients with overweight or obesity, while a decreased risk of overall obesity-associated cancer was observed in coagonist users.
Background
The study investigates whether weight loss induced by antiobesity medications can reduce the risk of obesity-associated cancers. Previous research has established a link between obesity and increased cancer risk, but the impact of pharmacologically induced weight loss on this risk remains unclear. This meta-analysis aims to provide clarity on this issue, particularly focusing on the role of coagonists like cagrilintide.
Methods
The study is a meta-analysis of randomized controlled trials sourced from PubMed, Embase, Cochrane Central Register of Controlled Trials, Web of Science, and ClinicalTrials.gov up to December 2024. It included 25 trials with a total of 40,731 participants. The primary outcome was the relative risk of obesity-associated cancer, analyzed using a random-effects model.
Results
The meta-analysis found no significant association between the use of AOMs and the risk of overall or site-specific obesity-associated cancers, with a relative risk of 1.03 (95% CI: 0.78 to 1.37). However, subgroup analysis indicated that coagonists significantly reduced the risk of overall obesity-associated cancer, with a relative risk of 0.43 (95% CI: 0.19 to 0.97). Additionally, every 5 kg weight reduction mediated by coagonists was marginally associated with a reduced cancer risk (RR=0.79, 95% CI: 0.62 to 1.00).
Interpretation
The findings suggest that while AOMs as a whole do not reduce cancer risk, coagonists like cagrilintide may offer a protective effect. This is consistent with the hypothesis that specific mechanisms of action in coagonists could influence cancer risk differently. However, the clinical significance of these findings is limited by the marginal statistical significance and the inherent limitations of meta-analysis data.
Key findings
- 25 RCTs included, n=40,731
- AOMs overall RR=1.03, 95% CI: 0.78 to 1.37
- Every 5 kg weight reduction RR=0.97, 95% CI: 0.84 to 1.12
- Coagonists RR=0.43, 95% CI: 0.19 to 0.97
- Every 5 kg weight reduction with coagonists RR=0.79, 95% CI: 0.62 to 1.00
Limitations
- Meta-analysis of existing trials
- Potential variability in trial methodologies
- Marginal statistical significance in coagonist subgroup
- No direct clinical trials on cancer outcomes
- Heterogeneity in participant characteristics